Introduction: In the randomized trial of standard-versus high-dose chemoradiotherapy for locally advanced (LA) NSCLC (Radiation Therapy Oncology Group 0617), overall survival (OS) was worse in the high-dose arm. Although heart dose was suggested as a contributing factor, actionable parameters have not been established. We present an analysis of clinical and dosimetric parameters affecting OS in this patient population, focusing on heart dose.
Introduction
Overall survival (OS) for patients with locally advanced (LA) NSCLC treated with definitive chemoradiotherapy is poor, with locoregional failure rates (in excess of 50%) significantly driving outcomes. [1] [2] [3] [4] Attempts to improve local control with dose escalation have met with mixed results, culminating with the definitive trial of standard-dose versus high-dose radiotherapy (Radiation Therapy Oncology Group [RTOG] 0617) revealing the disappointing result that OS was worse in the high-dose arm. 5 Although many causes of this outcome have been hypothesized and are being actively explored in multiple secondary analyses, one overriding concern is that poorly understood toxicity to an organ at risk (OAR) may have offset any potential improvement in OS derived from dose escalation. Underscoring this point, a multivariate analysis (MVA) of factors predictive of OS in RTOG 0617 identified heart dose as an independent predictor.
The true impact of heart dose has not yet been fully explored in this study population, and there are limitations to the granularity of clinical and dosimetric data that can be explored in cooperative group studies. Likewise, cardiac-specific toxicity has not been well reviewed in this patient population. Furthermore, no clinically actionable heart treatment planning parameters have been described to date. We present a comprehensive review of clinical outcomes after definitive radiotherapy for LA NSCLC, including an analysis of clinical and dosimetric parameters affecting OS in this patient population, with a focus on heart dose.
Methods and Materials

Study Design
An institutional review board-approved singleinstitution retrospective review was conducted on 416 patients with LA NSCLC treated at our institution from 2001-2015 with definitive radiotherapy with or without chemotherapy (57.4% received a platinum/taxol doublet, and 37.9% received a platinum/nontaxol doublet). Patients underwent chest computed tomography (CT) and physician follow-up every 3 to 6 months and were evaluated for local, regional, and distant failure. Toxicities were graded with the Common Terminology Criteria for Adverse Events (CTCAE) scoring system, version 4.0, using the following: patient followup notes; CT, positron emission tomography (PET)/CT, or magnetic resonance imaging; endoscopy; electrocardiography; echocardiography; and cardiac catheterization evaluation. In brief, cardiac toxicities were graded from 0 to 5 as follows for pericardial effusions, arrhythmia, acute coronary syndrome, valvular disease, congestive heart failure, and cardiac death: grade 0 (asymptomatic/incidental), 1 (mild to moderate), 2 (medical intervention), 3 (hospitalization/intensive care unit intervention), 4 (life-threatening), and 5 (death) (see the summary of cardiac toxicities [Supplementary Table 1] ). Patients with cardiac morbidities that preceded treatment and remained stable after therapy were not counted as treatment-related toxicities. Study data were collected and managed using the Research Electronic Data Capture electronic data capture tools hosted by the Biostatistics Division of Washington University School of Medicine. 6 A Charlson comorbidity index (CCI) score was also calculated for each patient on the basis of the 10-year mortality risk for patients with comorbidities, including acquired immunodeficiency syndrome, heart disease, and cancer. 7 The patient's current lung cancer diagnosis was not included in the CCI estimation, as this score was meant to evaluate pretreatment risk.
Radiation Therapy and Dosimetric Analysis
Of the 416 patients, 333 had viable Digital Imaging and Communications in Medicine-Radiation Therapy plans that were imported into the Computational Environment for Radiological Research software platform, where planning target volume (PTV) and OAR (the esophagus, right and left lungs, and heart) contours were reviewed and recontoured (if appropriate). A total of 333 patient hearts were recontoured according to the Wheatley et al. atlas prepared for secondary analysis of RTOG 0617. 8 The dosimetric parameters heart volume and esophagus volume refer to the size (volume in cm 3 ) of the recontoured structures. Lung dosimetry refers to the total lung, excluding the target volume. OAR V 5 to V 70 refers to the proportion (in either percent or cm 3 ) of the OAR receiving at least the indicated dose in Gy. Dosimetric data were extracted with Computational Environment for Radiological Research software, reviewed by a physician, and exported to the Research Electronic Data Capture database. Heart dose was correlated with clinical toxicity in 322 patients who had both viable Digital Imaging and Communications in Medicine-Radiation Therapy plans and clinical toxicity outcomes.
Statistical Methods
Follow-up time was calculated from the end of radiation therapy (RT). The end points for the study were OS (time from the start of RT until death from any cause) and disease-free survival (time from the start of RT until tumor progression). OS rates were estimated with the Kaplan-Meier method and compared using the log-rank test. The Cox regression model was used to estimate the hazard ratio (HR) and the corresponding 95% confidence interval (CI) for univariate analysis (UVA) and MVA. Multivariate model building was performed using stepwise regression (a modification of the forward selection method) techniques utilizing significant univariate factors to avoid overfitting the model. Patients with incomplete data for covariates considered in the multivariate model were assumed to be missing at random and were therefore removed from the analysis, leaving a total of 251 patients for the MVA.
A subset analysis of patients receiving concurrent chemoradiotherapy was also performed for comparison (n ¼ 200). Cutoff p values had to be 0.05 or less for entry into the model. The order of entry was determined according to the lowest p value at the time of entry into the stepwise regression analysis procedure. PTV volume, lung, and heart dosimetric parameters were subjected to cutpoint determinations on basis of the methodology of Contal and O'Quigley. 9 Heart volume was analyzed in 100-cm 3 segments and the other volumetric parameters were analyzed in 10% segments. The Wilcoxon rank sum analysis was used to determine whether heart variables differed between threedimensional conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT). Pearson's correlation coefficients were calculated for each pair of dosimetric parameters. Fisher's exact test compared CTCAE toxicities between 3D-CRT and IMRT. A p value of 0.05 or less was considered statistically significant. All statistical tests were two sided. All analysis was completed using the SAS software, version 9.4 (SAS Institute Inc., Cary, NC).
Results
Patient Outcomes
Patient and treatment characteristics are summarized in Table 1 . Most patients (66.7%) had the nonsquamous histologic type, and 78.5% received concurrent chemotherapy. Most (60.0%) were treated with 3D-CRT to a median of 66.0 Gy at 2.0 Gy per fraction. Median followup was 14.5 months (range 0-163) for all patients and 21.9 months for living patients. Median survival was 16.8 months (95% CI: 14.9-19.5). The 1-year and 2-year OS rates were 61.4% (95% CI: 56.4-66.0) and 38.8% (95% CI: 33.5-43.5), respectively (Fig. 1A) . The 1-and 2-year disease-free survival rates were 50.6% (95% CI: 45.0-56.0) and 31.3% (95% CI: 25.9-36.9), respectively (Supplementary Fig. 1 ). Treatment toxicities included esophagitis during treatment (grade 2, 67.5%; grade 3, 12.1%) and after treatment (grade 2, 11.2%; grade >3, 10.3%), pneumonitis (grade 2, 18.3%; grade 3, 10.3%; and grade 5, 0.5%), cardiac toxicity (grade 2, 27.5%; grade 3, 24.0%; and grade 5, 0.2%), brachial plexopathy (grade 2, 0.2%), and myelitis (grade 2, 0.5%) ( Table 2 ).
UVA and MVA Models of OS
A summary of factors associated with OS on UVA is presented in Supplementary Table 2 and Figure 2 . Patient characteristics such as male sex, higher CCI score, and current smoking were associated with worse OS. Tumor characteristics such as left lower lobe (LLL) location and bilateral mediastinal or hilar lymph node (LN) involvement were associated with worse OS. LLL tumors were more likely to have ipsilateral (p ¼ 0.01) or bilateral mediastinal (p ¼ 0.02) involvement, as well as higher heart V 5 to V 50 values (p < 0.03). Concurrent chemotherapy or the use of IMRT were associated with better OS. Whereas grade 4 pneumonitis was associated with poorer OS, grade 1 and 2 (HR ¼ 0.65) pneumonitis were associated with improved OS.
Multiple dosimetric parameters were associated with worse OS on UVA, including PTV volume, mean lung dose (MLD), lung V 5 to V 65 , heart volume (cm 3 ), mean heart dose, heart V 5 to V 60 , esophagus volume, minimum esophagus dose, mean esophagus dose, and esophagus V 5 to V 55 . Neither the prescription dose (physician prescription) nor any measure of dose to PTV (volumetric mean, minimum, or maximum dose determined during planning) was found to be associated with OS on UVA. Cutpoint analysis was performed on each heart dose metric; it revealed that all measures of increasing dose to heart except heart maximum dose were associated with poorer OS. The cutpoint analysis also showed that a PTV of 484 cm 2 or more (HR ¼ 1.66, p < 0.0001) and an MLD of 19 Gy or more (HR ¼ 1.67, p ¼ 0.0002) were associated with poorer OS.
MVA analysis demonstrated that heart V 50 (HR ¼ 1.23, p < 0.0001), heart volume (HR ¼ 1.12, p < 0.0001), lung V 5 (HR ¼ 1.01, p ¼ 0.03) (analyzed as continuous variables without cutpoints), and bilateral mediastinal LN involvement (HR ¼ 1.76, p ¼ 0.03) were independent negative predictors of OS, whereas concurrent chemotherapy (HR ¼ 0.50, p < 0.0001) was independently associated with better survival outcomes (Fig. 3A) . In the subset of patients treated with concurrent chemoradiotherapy, heart V 55 (HR ¼ 1.85, p < 0.01), heart volume (HR ¼ 1.10, p < 0.01), MLD (HR ¼ 1.07, p < .01), bilateral hilar LN involvement (HR ¼ 3.29, p ¼ 0.01), and LLL tumor location (HR ¼ 1.71, p ¼ 0.01) were independent negative predictors of OS (Fig. 3B ).
Heart V 50 as a Predictor of OS and Cardiac Toxicity OS was evaluated in patients dichotomized into groups, with heart V 50 less than 25% (n ¼ 225) and heart V 50 of at least 25% (n ¼ 108) (Fig. 1B) . The 1-year OS rates of V 50 less than 25% and V 50 of at least 25% were 70.2% and 46.8%, respectively (p < 0.0001). The 2-year OS rates of V 50 less than 25% and V 50 of at least 25% were 45.9% and 26.7%, respectively (p< 0.0001). Pearson's coefficient analysis showed that all of the heart parameters were significantly correlated, with r values in excess of 0.369 (p< 0.0001) (Supplementary Table 3 ). The percentage of treated patients with grade 1 or higher cardiac toxicity was 59.2%. When stratified by CTCAE cardiac toxicity grade (grade 0 versus grade 1), the median heart V 50 was significantly higher (20.8% versus 13.8%, p < 0.0001) for patients with a CTCAE cardiac toxicity grade of 1 or higher (grade 0, n ¼ 133; grade 1, n ¼ 189).
Patient Outcomes: IMRT versus 3D-CRT
IMRT has been used since 2010 for patients with LA NSCLC at our institution. Patients treated with IMRT had significantly worse Eastern Cooperative Oncology Group scores, fewer diagnostic mediastinoscopies, and more frequent PET-CT imaging, as well as a shift toward concurrent chemotherapy and away from induction and adjuvant chemotherapy, reflecting consistent changes in practice patterns during that time interval (Supplementary Table 4 ). Patients who received IMRT had a lower RT dose (63 vs 66 Gy, p< 0.0003). Although rates of esophagitis, brachial plexopathy, and myelitis incidents were not significantly different between patients undergoing 3D-CRT and those undergoing IMRT, pneumonitis (p¼ 0.0007) and cardiac toxicities (p < 0.0001) were significantly decreased in patients receiving IMRT (Fig. 4) . PET/CT, positron emission tomography/computed tomography scan; RT, radiation therapy; 3D-CRT, three-dimensional conformal radiation therapy; IMRT, intensity modulated radiation therapy; PTV, planning target volume.
Heart Dosimetry: IMRT versus 3D-CRT
IMRT decreased most heart dosimetric parameters, including maximum heart dose, mean heart dose, and heart V 15 to V 75 (p 0.0003) (Supplementary Table 5 ). The largest discrepancies were seen at the intermediate to high dose levels (V 20 , where there was >10% difference between treatment modalities), but not at the extremes, such as V 5 , V 75 , or minimum dose. Median heart V 50 values were significantly higher (24.7% versus 10.2%, p < 0.0001) for 3D-CRT versus IMRT, respectively.
Discussion
In a comprehensive review of clinical outcomes and predictors of OS in a large cohort of patients undergoing definitive radiotherapy for LA NSCLC, we have identified increasing heart dose as an independent dosimetric predictor of worse OS, even after accounting for wellestablished patient-and tumor-related predictors of OS. Heart V 50 was established as the strongest predictor of the heart metrics, and cutpoint analysis revealed that keeping heart V 50 at less than 25% is associated with nearly a 20% absolute improvement in 2-year OS. Although IMRT was not independently associated with improved OS on MVA, IMRT was associated with decreased heart dose and lower rates of cardiac toxicity compared with 3D-CRT.
Although the heart V 50 was selected by the multivariate model as the most important heart parameter, all of the heart parameters were significantly correlated with the heart V 50 . Furthermore, analysis of the concurrent chemoradiotherapy subset showed heart V 55 as the most important parameter. Therefore, it is likely more accurate to conclude that heart dosimetry as a whole is important for patient outcomes rather than emphasizing just one parameter.
That thoracic radiation can lead to heart toxicity is not in and of itself a new concept. Elegant analyses in patients with breast cancer and lymphoma show that up to 20% of patients can have elevated rates of heart disease, including pericarditis, acute coronary syndrome, and congestive heart failure. A study by Darby et al. . The 1-year OS was 61%, and the 2-year OS was 38%. (B) KaplanMeier curves for OS in patients with locally advanced NSCLC dichotomized by a heart V 50 value less than 25% (blue) versus a heart V 50 value of at least 25% (red) (p < 0.0001). The number at risk is shown below the graph at each time interval (in months). The 1-year OS was 70.2% (V 50 < 25%) versus 46.8% (V 50 25%), and the 2-year OS was 45.9% (V 50 < 25%) versus 26.7% (V 50 25%). heart V 50 < 25%, less than 25% of the heart receiving at least 50 Gy; heart V 50 25%, at least 25% of the heart receiving at least 50 Gy.
showed a linear increase in major cardiac events of 7.4%/Gy (mean heart dose), without apparent threshold, in treated patients with breast cancer. 10, 11 However, these studies look at heart toxicity as a late side effect of radiotherapy, something that was not previously extrapolated to patient populations with median survival times typically less than 2 years. Data regarding RT-related cardiac toxicity in the population of patients with NSCLC are limited. A French study of postoperative patients with NSCLC randomized to no further therapy versus RT showed a threefold excess of cardiac mortality in irradiated patients. 12 In addition to the results of Table 3 for additional variables and associated p values). Heart dosimetry variables are listed in red; lung dosimetry is listed in blue. RT, radiation therapy; CCI, Charlson comorbidity index; LLL, left lower lobe; LN, lymph node; PTV, planning target volume; cc, cubic centimeters/milliliters; V 5 , volume of the organ receiving at least 5 Gy. RTOG 0617, an M. D. Anderson study suggested that a mean heart dose 9.9 Gy or higher (the 25th percentile) was a negative predictor of OS. 13 Reducing the toxicity of our current treatments not only has implications for patient morbidity and survival, but also might reduce health care costs in this patient population, which garners 20% of Medicare's total expenditures for cancer.
14 A Surveillance, Epidemiology, and End Results-Medicare study of data from [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] showed that the long-term cost of lung cancer and cardiac deaths of patients with NSCLC had increased by 7.9% and 21.3% during the 10 years of the study, casting a veritable shadow on the individual for the rest of his or her life. 15 By identifying clinical, anatomical, disease, and dosimetric factors that affect patient survival, we can tailor treatment planning to safely escalate tumor dose. When patients are seen in consultation, clinical factors such as age, CCI score/comorbidities, and cardiac risk can guide decision making regarding the safety of dose escalation. Future studies can identify patients with elevated cardiac risk by using pretreatment cardiac risk algorithms for screening. Anatomical or disease parameters such as heart size or PTV can guide management by providing pretreatment risk factors. Why a larger heart volume should be a negative predictor for survival is unclear. That heart volume continued to be a predictor for OS outcome on MVA alongside heart V 50 suggests that it may not be just a dosimetric parameter, but also possibly a signifier for elevated pretreatment cardiac morbidity. Elevated total heart index volume (as evaluated by magnetic resonance imaging) in pediatric patients has been associated with structural disease and hypertrophic cardiomyopathy. 16 Although the disparate physiology in these patients should not be extrapolated to adult patients, it seems intuitive that larger heart volumes may be a corollary for cardiomegaly in patients with cardiac risk factors; however, this must be investigated further.
Dosimetric parameters such as dose to lung, heart, and esophagus variables were found to be predictors on UVA and demonstrate that normal tissue toxicity affects overall treatment efficacy. Lung V 5 was associated with OS within our multivariate model, although the HR was 1.01 (p ¼ 0.03). The equivocal HR value taken with the RTOG 0617 analysis showing that lung V 5 was not a predictor of OS or radiation pneumonitis (RP) suggests that lung V 5 has a low impact on OS in this patient population and is therefore unlikely to be clinically significant. 5 In this study, IMRT was a predictor of survival in UVA (consistent with data previously presented), 17, 18 with an HR similar to that with the use of concurrent chemotherapy, but was not a predictor for OS on MVA. Treatment with IMRT is now standard in our institution. Comparison of the patient characteristics for IMRT reflects many changes in our NSCLC treatment approach-increased PET-CT imaging and fewer mediastinoscopies, as well as increased use of concurrent chemotherapy and decreased induction and adjuvant chemotherapy. However, not only did patients treated with IMRT have fewer incidents of RP and cardiac toxicity, but they also had improved heart dosimetric parameters, especially at doses greater than 20 Gy. Therefore, heart V 50 is but one of many OAR parameters that can be minimized with IMRT to affect survival. This study demonstrates that advanced treatment modalities such as IMRT can lower heart dose and improve lung and heart toxicities, and it paves the way for future trials incorporating proton therapy (such as RTOG 1308) on the basis of prior data showing reduced lung, heart, esophagus, and bone marrow dose. 19, 20 An outstanding area of inquiry is the physiology of OAR toxicity. This comprehensive multiorgan dosimetric evaluation underscores the complex interplay between treated organs in the development of treatment toxicity. For example, CTCAE-graded cardiac toxicity was not a significant parameter on UVA (p > 0.311 for grade 0-4 cardiac toxicity [see Supplementary Table 2 ]) or MVA, possibly because the most common toxicity was pericardial effusions incidentally noted on follow-up imaging. Whereas grade 4 pneumonitis was a negative predictor for OS on UVA (reference: grade 0), grade 1 or 2 pneumonitis was associated with a better outcome, although the etiology remains to be determined. Use of an RP nomogram accounting for superior-inferior gross tumor volume position and MLD, 21 which has been validated on patients undergoing IMRT, 22 was significant on UVA but nevertheless showed an HR of approximately 1. Prior data from Huang et al. showed that with RP risk as the primary end point, a model incorporating heart (specifically, V 65 ) and lung variables was more accurate than one using lung variables alone. 23 These findings hint at a relationship between the heart and lung dosimetry, which requires further elucidation.
Our study has multiple limitations, including the fact that it is a retrospective, single-institution study in which 21.5% of patients did not receive concurrent chemotherapy and patients were evaluated over multiple treatment eras (encompassing multiple dose/fractionation regimens, the transition of 3D-CRT to IMRT, and the current inclusion of proton therapy-although the latter patients were excluded from this analysis). The cardiac toxicity follow-up is short-term. As already mentioned, attendant to any dosimetric study is the existing likelihood that dosimetric parameters interact with each other, making isolated OAR analysis challenging. This study does not intend to claim that heart dosimetry is the only factor critical to survival, only that heart dose can be optimized and may improve survival. Furthermore, it is the largest evaluation of comprehensive dosimetry and clinical parameters in this patient population that uses the heart contouring method of RTOG 0617. Therefore, this study provides useful insights while the secondary analysis is being completed. The goal of this paper is not to build a definitive predictive model, but to provide a hypothesis-generating model. Therefore, independent analysis of other data sets must be performed to validate these data. These findings have the potential to be practice changing by providing actionable goals in treatment planning that may afford safe dose escalation for more effective tumor therapy.
